Marker Therapeutics (MRKR) Interest Coverage Ratio (2010 - 2026)

Marker Therapeutics (MRKR) posted quarterly Interest Coverage Ratio of 11.49 for Q1 2026, down 243.6% quarter-over-quarter from 3.34 in Q4 2025.

Marker Therapeutics (MRKR) Interest Coverage Ratio (2010 - 2026) Analysis & Trends

Marker Therapeutics (MRKR) has reported Interest Coverage Ratio for 16 consecutive years, with 11.49 the latest figure, recorded in Q1 2026.

In Q1 2026, Interest Coverage Ratio changed N/A year-over-year to 11.49; the TTM figure through Mar 2026 stood at 34.86 (down 456.33% YoY), while the FY2025 annual figure was 0.3, down 9.71% from the prior year.
Interest Coverage Ratio retreated to 11.49 in Q1 2026 per MRKR's latest filing, from 3.34 in the prior quarter.
Across five years, Interest Coverage Ratio topped out at 0.36 in Q2 2022 and bottomed at 387.37 in Q2 2025.
Historically, Interest Coverage Ratio has averaged 32.52 across 5 years, with a median of 3.54 in 2024.
Annual changes were most pronounced in 2023 — Interest Coverage Ratio surged 98.49% — and 2025, when it plunged 19939.11%.
Marker Therapeutics' Interest Coverage Ratio stood at 14.75 in 2022, then soared by 84.88% to 2.23 in 2023, then tumbled by 358.32% to 10.22 in 2024, then surged by 67.28% to 3.34 in 2025, then sank by 243.6% to 11.49 in 2026.
Business Quant data shows MRKR's Interest Coverage Ratio at 11.49 in Q1 2026, 3.34 in Q4 2025, and 387.37 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Cover (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	117.59
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	8.18
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	2.82
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.08
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	1.42
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	76.86
10	Marker Therapeutics	23.95 Mn	12.02 Mn	-	-

Download Data